

Serenella M Pupa

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4594194/publications.pdf>

Version: 2024-02-01

74
papers

3,815
citations

159358

30
h-index

123241

61
g-index

79
all docs

79
docs citations

79
times ranked

5488
citing authors

#	ARTICLE	IF	CITATIONS
1	Potential role of HER2-overexpressing exosomes in countering trastuzumab-based therapy. <i>Journal of Cellular Physiology</i> , 2012, 227, 658-667.	2.0	410
2	Characterization of human ovarian carcinoma-associated antigens defined by novel monoclonal antibodies with tumor-restricted specificity. <i>International Journal of Cancer</i> , 1987, 39, 297-303.	2.3	284
3	New insights into the role of extracellular matrix during tumor onset and progression. <i>Journal of Cellular Physiology</i> , 2002, 192, 259-267.	2.0	279
4	Role of HER2 gene overexpression in breast carcinoma. <i>Journal of Cellular Physiology</i> , 2000, 182, 150-162.	2.0	258
5	Combined Allogeneic Tumor Cell Vaccination and Systemic Interleukin 12 Prevents Mammary Carcinogenesis in HER-2/neu Transgenic Mice. <i>Journal of Experimental Medicine</i> , 2001, 194, 1195-1206.	4.2	218
6	Electroporated DNA Vaccine Clears Away Multifocal Mammary Carcinomas in Her-2/neu Transgenic Mice. <i>Cancer Research</i> , 2004, 64, 2858-2864.	0.4	143
7	WNT signaling modulates PD-L1 expression in the stem cell compartment of triple-negative breast cancer. <i>Oncogene</i> , 2019, 38, 4047-4060.	2.6	137
8	Improved Clinical Outcome in Indolent B-Cell Lymphoma Patients Vaccinated with Autologous Tumor Cells Experiencing Immunogenic Death. <i>Cancer Research</i> , 2010, 70, 9062-9072.	0.4	126
9	Oncogenic protein tyrosine kinases. <i>Cellular and Molecular Life Sciences</i> , 2004, 61, 2965-2978.	2.4	125
10	Role of exon-16-deleted HER2 in breast carcinomas. <i>Endocrine-Related Cancer</i> , 2006, 13, 221-232.	1.6	112
11	Vaccination with autologous tumor-loaded dendritic cells induces clinical and immunologic responses in indolent B-cell lymphoma patients with relapsed and measurable disease: a pilot study. <i>Blood</i> , 2009, 113, 18-27.	0.6	99
12	HER2 as a target for breast cancer therapy. <i>Expert Opinion on Biological Therapy</i> , 2010, 10, 711-724.	1.4	78
13	Biomarkers of Primary Resistance to Trastuzumab in HER2-Positive Metastatic Gastric Cancer Patients: the AMNESIA Case-Control Study. <i>Clinical Cancer Research</i> , 2018, 24, 1082-1089.	3.2	76
14	p185neu protein is required for tumor and anchorage-independent growth, not for cell proliferation of transgenic mammary carcinoma. <i>International Journal of Cancer</i> , 2000, 87, 186-194.	2.3	75
15	RET fusions in a small subset of advanced colorectal cancers at risk of being neglected. <i>Annals of Oncology</i> , 2018, 29, 1394-1401.	0.6	72
16	Human ovarian carcinoma lysis by cytotoxic t cells targeted by bispecific monoclonal antibodies: Analysis of the antibody components. <i>International Journal of Cancer</i> , 1988, 41, 609-615.	2.3	70
17	The Human Splice Variant Δ^{16} HER2 Induces Rapid Tumor Onset in a Reporter Transgenic Mouse. <i>PLoS ONE</i> , 2011, 6, e18727.	1.1	70
18	The 67 kDa laminin receptor increases tumor aggressiveness by remodeling laminin-1. <i>Endocrine-Related Cancer</i> , 2005, 12, 393-406.	1.6	69

#	ARTICLE	IF	CITATIONS
19	Activated d16HER2 Homodimers and SRC Kinase Mediate Optimal Efficacy for Trastuzumab. <i>Cancer Research</i> , 2014, 74, 6248-6259.	0.4	63
20	Prevention of spontaneous neu-expressing mammary tumor development in mice transgenic for rat proto-neu by DNA vaccination. <i>Gene Therapy</i> , 2001, 8, 75-79.	2.3	61
21	Killing of Laminin Receptor-Positive Human Lung Cancers by Tumor-Infiltrating Lymphocytes Bearing $\hat{\Gamma}^{\hat{\Gamma}}$ + T-Cell Receptors. <i>Journal of the National Cancer Institute</i> , 1996, 88, 436-441.	3.0	60
22	Identification of Breast Cancer-Restricted Antigens by Antibody Screening of SKBR3 cDNA Library Using a Preselected Patient's Serum. <i>Breast Cancer Research and Treatment</i> , 2002, 73, 245-256.	1.1	59
23	Regulation of Breast Cancer Response to Chemotherapy by Fibulin-1. <i>Cancer Research</i> , 2007, 67, 4271-4277.	0.4	59
24	Immunological and pathobiological roles of fibulin-1 in breast cancer. <i>Oncogene</i> , 2004, 23, 2153-2160.	2.6	45
25	Activation of mononuclear cells to be used for hybrid monoclonal antibody-induced lysis of human ovarian carcinoma cells. <i>International Journal of Cancer</i> , 1988, 42, 455-459.	2.3	41
26	HSPH1 inhibition downregulates Bcl-6 and c-Myc and hampers the growth of human aggressive B-cell non-Hodgkin lymphoma. <i>Blood</i> , 2015, 125, 1768-1771.	0.6	40
27	SEL1L a multifaceted protein playing a role in tumor progression. <i>Journal of Cellular Physiology</i> , 2006, 208, 23-38.	2.0	36
28	Pathobiological implications of the d16HER2 splice variant for stemness and aggressiveness of HER2-positive breast cancer. <i>Oncogene</i> , 2017, 36, 1721-1732.	2.6	36
29	Distinct pattern of HSP72 and monomeric laminin receptor expression in human lung cancers infiltrated by $\hat{\Gamma}^{\hat{\Gamma}}$ T lymphocytes. <i>International Journal of Cancer</i> , 1994, 57, 486-490.	2.3	34
30	Inhibition of mammary carcinoma development in HER-2/neu transgenic mice through induction of autoimmunity by xenogeneic DNA vaccination. <i>Cancer Research</i> , 2005, 65, 1071-8.	0.4	33
31	Activity and resistance of trastuzumab according to different clinical settings. <i>Cancer Treatment Reviews</i> , 2012, 38, 212-217.	3.4	31
32	Intratumor lactate levels reflect HER2 addiction status in HER2-positive breast cancer. <i>Journal of Cellular Physiology</i> , 2019, 234, 1768-1779.	2.0	31
33	HER-2: A biomarker at the crossroads of breast cancer immunotherapy and molecular medicine. <i>Journal of Cellular Physiology</i> , 2005, 205, 10-18.	2.0	30
34	Serological identification of HSP105 as a novel non-Hodgkin lymphoma therapeutic target. <i>Blood</i> , 2011, 118, 4421-4430.	0.6	30
35	Anin vivo model to compare human leukocyte infiltration in carcinoma xenografts producing different chemokines. <i>International Journal of Cancer</i> , 1995, 62, 572-578.	2.3	29
36	Shed HER2 extracellular domain in HER2-mediated tumor growth and in trastuzumab susceptibility. <i>Journal of Cellular Physiology</i> , 2010, 225, 256-265.	2.0	28

#	ARTICLE	IF	CITATIONS
37	HER2 Signaling and Breast Cancer Stem Cells: The Bridge behind HER2-Positive Breast Cancer Aggressiveness and Therapy Refractoriness. <i>Cancers</i> , 2021, 13, 4778.	1.7	27
38	Cancer Stem Cells: Devil or Savior? Looking behind the Scenes of Immunotherapy Failure. <i>Cells</i> , 2020, 9, 555.	1.8	26
39	Murine granulocytes control human tumor growth in SCID mice. <i>International Journal of Cancer</i> , 2000, 87, 569-573.	2.3	24
40	Increased overall survival independent of RECIST response in metastatic breast cancer patients continuing trastuzumab treatment: evidence from a retrospective study. <i>Breast Cancer Research and Treatment</i> , 2011, 128, 147-154.	1.1	23
41	Synergistic Activation upon MET and ALK Coamplification Sustains Targeted Therapy in Sarcomatoid Carcinoma, a Deadly Subtype of Lung Cancer. <i>Journal of Thoracic Oncology</i> , 2016, 11, 718-728.	0.5	22
42	The landscape of d16HER2 splice variant expression across HER2-positive cancers. <i>Scientific Reports</i> , 2019, 9, 3545.	1.6	22
43	The d16HER2 Splice Variant: A Friend or Foe of HER2-Positive Cancers?. <i>Cancers</i> , 2019, 11, 902.	1.7	21
44	Impact of systemic and tumor lipid metabolism on everolimus efficacy in advanced pancreatic neuroendocrine tumors (pNETs). <i>International Journal of Cancer</i> , 2019, 144, 1704-1712.	2.3	20
45	Ectopic expression of pRb2/p130 suppresses the tumorigenicity of the c-erbB-2-overexpressing SKOV3 tumor cell line. <i>Oncogene</i> , 1999, 18, 651-656.	2.6	19
46	HER2 isoforms co-expression differently tunes mammary tumor phenotypes affecting onset, vasculature and therapeutic response. <i>Oncotarget</i> , 2017, 8, 54444-54458.	0.8	19
47	Anti-ovarian carcinoma anti-T3 heteroconjugates or hybrid antibodies induce tumor cell lysis by cytotoxic T-cells. <i>International Journal of Cancer</i> , 1988, 41, 18-21.	2.3	17
48	Inhibition of the Wnt Signalling Pathway: An Avenue to Control Breast Cancer Aggressiveness. <i>International Journal of Molecular Sciences</i> , 2020, 21, 9069.	1.8	16
49	Do pre-diagnostic drinking habits influence breast cancer survival?. <i>Tumori</i> , 2011, 97, 142-8.	0.6	16
50	Curability of advanced Burkitt's lymphoma in children by intensive short-term chemotherapy. <i>European Journal of Cancer</i> , 1993, 29, 692-698.	1.3	15
51	Phenethyl isothiocyanate hampers growth and progression of HER2-positive breast and ovarian carcinoma by targeting their stem cell compartment. <i>Cellular Oncology (Dordrecht)</i> , 2019, 42, 815-828.	2.1	11
52	BCL6 and the Notch pathway: a signaling axis leading to a novel druggable biotarget in triple negative breast cancer. <i>Cellular Oncology (Dordrecht)</i> , 2022, 45, 257-274.	2.1	9
53	Apoptosis Induction by Trastuzumab: Possible Role of the Core Biopsy Intervention. <i>Journal of Clinical Oncology</i> , 2005, 23, 7238-7240.	0.8	8
54	The HER2 World: Better Treatment Selection for Better Outcome. <i>Journal of the National Cancer Institute Monographs</i> , 2011, 2011, 82-85.	0.9	7

#	ARTICLE	IF	CITATIONS
55	Identification of Relevant Conformational Epitopes on the HER2 Oncoprotein by Using Large Fragment Phage Display (LFPD). PLoS ONE, 2013, 8, e58358.	1.1	7
56	Monoclonal antibody to fibulin-1 generated by genetic immunization. Journal of Cellular Biochemistry, 2003, 89, 647-652.	1.2	6
57	T Cells Expressing Receptor Recombination/Revision Machinery Are Detected in the Tumor Microenvironment and Expanded in Genomically Over-unstable Models. Cancer Immunology Research, 2021, 9, 825-837.	1.6	6
58	Humoral immune response for early diagnosis of breast carcinoma. Annals of Oncology, 2002, 13, 483.	0.6	5
59	Fifteen-year follow-up of relapsed indolent non-Hodgkin lymphoma patients vaccinated with tumor-loaded dendritic cells. , 2021, 9, e002240.		4
60	p185neu protein is required for tumor and anchorage-independent growth, not for cell proliferation of transgenic mammary carcinoma. , 2000, 87, 186.		3
61	Vascular endothelial growth factor A (VEGF-A) amplification and long-term response to ramucirumab (ram) in metastatic gastric cancer (mGC): The VERA study.. Journal of Clinical Oncology, 2019, 37, 3143-3143.	0.8	3
62	Re: Italian Randomized Trial Among Women With Hysterectomy: Tamoxifen and Hormone-Dependent Breast Cancer in High-Risk Women. Journal of the National Cancer Institute, 2003, 95, 917-918.	3.0	1
63	HSP105 Inhibition Counteracts Key Oncogenic Pathways and Hampers the Growth of Human Aggressive B-Cell Non-Hodgkin Lymphoma. Blood, 2012, 120, 1562-1562.	0.6	1
64	Anticancer innovative therapy: Highlights from the ninth annual meeting. Cytokine and Growth Factor Reviews, 2020, 51, 1-9.	3.2	0
65	Abstract 916: Role of delta16HER2 splice variant in HER2-driven tumor progression and response to targeted therapy. , 2012, , .		0
66	Abstract 2774: Coexpression of Delta16 isoform and full-length HER-2 in F1 hybrid transgenic mice: effects on tumor growth and malignancy. , 2014, , .		0
67	Abstract 2637: Role of d16HER2 splice variant in HER2-positive breast cancer. , 2014, , .		0
68	Abstract 2314: d16HER2 splice variant regulates the activity of HER2-positive breast cancer-initiating cells. , 2015, , .		0
69	Abstract 5015: Tumor dependence on HER2 signaling as a player in immune infiltration required for trastuzumab activity. , 2015, , .		0
70	Abstract 1200: HER-2 isoform interaction in mammary carcinoma onset and progression. , 2016, , .		0
71	Abstract 3826: Phenethyl isothiocyanate hampers growth and progression of HER2-positive breast cancers. , 2016, , .		0
72	Abstract 5428: Lactate production as a potential marker of HER2-addiction and Trastuzumab susceptibility. , 2017, , .		0

#	ARTICLE	IF	CITATIONS
73	Abstract A068: Targeting glioblastoma stem cells through a MET inhibitor. , 2018, , .		0
74	Abstract P3-02-01: Fatty acid uptake as a potentially new resistance mechanism to anti-HER2 treatments in HER2-positive breast cancer. , 2020, , .		0